Ovarian cancer spheroid shrinkage following continuous exposure to cisplatin is a function of spheroid diameter

Tanenbaum, Laura M.; Mantzavinou, Aikaterini; Subramanyam, Kriti S.; Carmen, Marcela G. del; Cima, Michael J.

doi:10.1016/j.ygyno.2017.04.014

Cited by 15 publications

(20 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified negative correlations between organoid size and oxaliplatin sensitivity in both culture types for various concentrations, demonstrating that larger organoids were more susceptible to OxPt chemotherapy (Figure 2E–2I ). This contradicts previous investigations that demonstrated a positive correlation between organoid size and cisplatin susceptibility in ovarian cancer models [ 27 ]. Our findings demonstrate reduced OxPt efficacy in AsPC-1 organoids compared to MIA PaCa-2 organoids even in nodules of comparable sizes (Figure 2E–2I ), indicating that organoid size alone does not account for the OxPt resistance in AsPc-1 nodules.…”

Section: Resultscontrasting

confidence: 99%

“…The results of this study correlated well with previous findings on the BPD-PDT-susceptibility of PANC-1 organoids [ 27 ], and MIA PaCa-2 organoids [ 19 ]. Although the AsPC-1 organoids in the current study demonstrated substantial PDT-resistance in comparison to previous findings, these can be attributed to subtle differences in the experimental design [ 27 ] as it was previously demonstrated that variations in PDT dose parameters can have a great impact on the treatment outcomes [ 22 , 39 ]. However, our findings on the effects of PDT on organoid cultures of PanCa contrasts with previous findings reported for ovarian cancer organoids.…”

Section: Discussionsupporting

confidence: 91%

“…Previous investigations have demonstrated that platinum-based chemotherapeutics are capable of diffusing throughout entire organoids with higher concentrations at the organoid peripheries [ 25 , 26 ]. However, studies on ovarian cancer organoids showed that there was a correlation between nodule size and cisplatin efficacy [ 27 ]. With respect to PDT, previous studies have demonstrated that BPD has a limited diffusion range that was sufficient to completely photosensitize small organoids, yet photosensitization was restricted to the periphery of larger organoids [ 28 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Neoadjuvant photodynamic therapy augments immediate and prolonged oxaliplatin efficacy in metastatic pancreatic cancer organoids

et al. 2018

View full text Add to dashboard Cite

Effective treatment of advanced metastatic disease remains the primary challenge in the management of inoperable pancreatic cancer. Current therapies such as oxaliplatin (OxPt)-based chemotherapy regimens (FOLFIRINOX) provide modest short-term survival improvements, yet with significant toxicity. Photodynamic therapy (PDT), a light-activated cancer therapy, demonstrated clinical promise for pancreatic cancer treatment and enhances conventional chemotherapies with non-overlapping toxicities. This study investigates the capacity of neoadjuvant PDT using a clinically-approved photosensitizer, benzoporphyrin derivative (BPD, verteporfin), to enhance OxPt efficacy in metastatic pancreatic cancer. Treatment effects were evaluated in organotypic three-dimensional (3D) cultures, clinically representative models that bridge the gap between conventional cell cultures and in vivo models. The temporally-spaced, multiparametric analyses demonstrated a superior efficacy for combined PDT+OxPt compared to each monotherapy alone, which was recapitulated on different organotypic pancreatic cancer cultures. The therapeutic benefit of neoadjuvant PDT to OxPt chemotherapy materialized in a time-dependent manner, reducing residual viable tissue and tumor viability in a manner not achievable with OxPt or PDT alone. These findings emphasize the need for intelligent combination therapies and relevant models to evaluate the temporal kinetics of interactions between mechanistically-distinct treatments and highlight the promise of PDT as a neoadjuvant treatment for disseminated pancreatic cancer.

show abstract

Section: Resultscontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 91%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Neoadjuvant photodynamic therapy augments immediate and prolonged oxaliplatin efficacy in metastatic pancreatic cancer organoids

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Main causes for low survival rate of OC include low early diagnosis and susceptibility to recurrence or metastasis. Previous studies showed that in addition to unique characteristics of OC, less sensitivity of OC cells to chemotherapeutic drugs was also a cause for recurrence, metastasis and then failure of tumor treatment (13,14). Since targeted therapy is a means for tumor treatment by selective inhibition of molecular pathway, a question is raised that whether selective targeted therapy may be provided for the resistance mechanism.…”

Section: Discussionmentioning

confidence: 99%

PTPRZ1 Inhibits the Cisplatin Resistance of Ovarian Cancer by Regulating PI3K/AKT/mTOR Signal Pathway

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Cisplatin resistance (DDP resistance) is a major cause for poor prognosis of ovarian cancer patients. PTPRZ1 has been proven to participate in the occurrence and development of multiple tumors, including tumor resistance. This study was designed to investigate the roles of PTPRZ1 in DDP-resistant ovarian cancer cells and their possible mechanism.Methods: PTPRZ1 expression in ovarian cancer tissues and normal tissues was analyzed by GEPIA database and verified by qRT-PCR. PTPRZ1 expression in normal ovarian cancer cells and DDP-resistant ovarian cancer cells was also analyzed. Subsequently, qRT-PCR, western blot, MTT experiment and flow cytometry were used to assess the effects of PTPRZ1-PI3K/AKT/mTOR regulating axis on cisplatin resistance of ovarian cancer.Results: PTPRZ1 expression was abnormally low in ovarian cancer tissues, and notably reduced in DDP-resistant ovarian cancer cells. MTT experiment and flow cytometer indicated that overexpression of PTPRZ1 enhanced the cisplatin sensitivity of ovarian cancer cells and promoted the cell apoptosis. The results of mechanism research showed that PTPRZ1 exerted its biological effects possibly through blocking PI3K/AKT/mTOR pathway.Conclusion: PTPRZ1 suppresses the cisplatin resistance of ovarian cancer and induces the cytotoxicity by blocking PI3K/AKT/mTOR pathway.

show abstract

“…PTX, as such has poor aqueous solubility, low bioavailability and is often associated with dose-limiting toxicities and other side effects [12][13][14]. By loading PTX in different delivery systems, we have demonstrated the improved therapeutic outcome in ovarian cancer cells [15,16].…”

Section: Introductionmentioning

confidence: 90%

Sustained release paclitaxel-loaded core-shell-structured solid lipid microparticles for intraperitoneal chemotherapy of ovarian cancer

Han

Dwivedi

Mangrio

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

show abstract

Ovarian cancer spheroid shrinkage following continuous exposure to cisplatin is a function of spheroid diameter

Cited by 15 publications

References 33 publications

Neoadjuvant photodynamic therapy augments immediate and prolonged oxaliplatin efficacy in metastatic pancreatic cancer organoids

Neoadjuvant photodynamic therapy augments immediate and prolonged oxaliplatin efficacy in metastatic pancreatic cancer organoids

PTPRZ1 Inhibits the Cisplatin Resistance of Ovarian Cancer by Regulating PI3K/AKT/mTOR Signal Pathway

Sustained release paclitaxel-loaded core-shell-structured solid lipid microparticles for intraperitoneal chemotherapy of ovarian cancer

Contact Info

Product

Resources

About